Pain management, gastrointestinal, anxiety, sleep and dermatologic issues

(Study Evaluating Real-Life Experience and Efficacy of CBD Treatment) 

SELECT is an IRB-approved Observational Study aimed at evaluating patients’ experiences and/or perceptions and patient response for those who have been prescribed a CBD tincture or topical formulation by their clinician. Pain management, Anxiety, Sleep, Gastrointestinal, and Dermatologic symptoms will be evaluated  by  patient  answers  to  validated  measurement  scales  (e.g.;  Brief  Pain  Inventory  (BPI), Gastrointestinal  Quality  of  Life  Index  (GIQLI-10),  The  Pittsburgh  Sleep  Quality  Index  (PSQI),  The  Hospital Anxiety and Depression Scale (HADS), and the Acne Quality of Life Questionnaire (Acne-Qol)) as  well  as  additional  survey  questions  regarding  patient  satisfaction,   current  medication  usage,  and resumption of their normal activities.

The purpose of this minimal risk, observational study is to evaluate patients with mild, moderate, or chronic pain symptoms, sleep disorders, gastrointestinal disorders, anxiety disorder or dermatologic conditions (i.e. acne) and evaluate perceptions and efficacy of CBD treatment after the use of a CBD tincture or topical formulation.

Brief  Pain  Inventory  (BPI), Gastrointestinal  Quality  of  Life  Index  (GIQLI-10),  The  Pittsburgh  Sleep  Quality  Index  (PSQI),  The  Hospital Anxiety and Depression Scale (HADS), and the Acne Quality of Life Questionnaire (Acne-Qol)) as  well  as  additional  survey  questions  regarding  patient  satisfaction, current  medication  usage,  and resumption of their normal activities.

To learn more about our SELECT study, please call our dedicated Healthcare Provider HelpDesk at (800) 616-9403.